title: [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].
abstract: OBJECTIVE
  To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension.
  
  
  METHODS
  This was a multicenter, randomized, double-blind, placebo and active antihypertensive drug parallel-controlled study. After 2 weeks of placebo run-in period, 315 patients at 6 centers with diastolic blood pressure (DBP) between 95 to 109 mm Hg (1 mm Hg = 0.133 kPa) while systolic blood pressure (SBP) below 180 mm Hg were randomized to receive aranidipine 5-20 mg/d (n = 126) or retard-released felodipine 5-10 mg/d (n = 126) for 12 weeks. Others (n = 63) received placebo for 4 weeks. Their blood pressures were evaluated at baseline and the end of Weeks 4, 8 and 12.
  
  
  RESULTS
  After a 12-week treatment, SBP decreased from 148.8 ± 10.7 mm Hg to (132.8 ± 11.2) mm Hg while DBP dropped from ( 98.4 ± 2.8) mm Hg to (83.9 ± 7.5) mm Hg. There were significant differences with the baseline values (P < 0.0001). After a 4-week treatment, the reductions of SBP in aranidipine and retard-released felodipine groups were (12.1 ± 11.0) mm Hg and (12.2 ± 11.2) mm Hg while the reductions of DBP in two groups (11.8 ± 6.9) mm Hg and (12.1 ± 7.9) mm Hg respectively. The reductions of SBP and DBP in two groups were (2.3 ± 8.4) mm Hg and (4.0 ± 5.1) mm Hg and they were significantly superior to that in placebo group (P < 0.0001). But no significant difference existed between aranidipine and retard-released felodipine groups. Also no significant differences were found between these two antihypertensive therapy groups at the end of Weeks 4, 8 and 12 in the reduction of blood pressure, total response rate and blood pressure control rate. But 20 mg daily aranidipine was significantly superior to 10 mg daily retard-released felodipine in the control rates of SBP and DBP. Adverse events occurred at 24.22% and 29.92% in aranidipine and retard-released felodipine groups respectively (P = 0.305).
  
  
  CONCLUSIONS
  Administration of aranidipine 5-20 mg/d can effectively control blood pressure and is not inferior to retard-released felodipine 5-10 mg/d. The efficacy of 20 mg/d aranidipine is superior to that of retard-released felodipine 5-10 mg/d. And the effectiveness and safety of aranidipine are similar to those of retard-released felodipine.
authors.affiliation: Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Jiao
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Jia-tong
authors.initials: JT
authors.lastname: Zheng
authors.affiliation: Email: Keyuannan6666@yahoo.com.cn.
authors.forename: Yuan-nan
authors.initials: YN
authors.lastname: Ke
authors.forename: Yun
authors.initials: Y
authors.lastname: Wang
authors.forename: Han-yue
authors.initials: HY
authors.lastname: Yang
authors.forename: Hao
authors.initials: H
authors.lastname: Jin
authors.forename: Xiu-li
authors.initials: XL
authors.lastname: Zhao
authors.forename: Mei-xia
authors.initials: MX
authors.lastname: Liu
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Bang-yu
authors.initials: BY
authors.lastname: Wang
authors.forename: Dong-ye
authors.initials: DY
authors.lastname: Li
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D000075222:Essential Hypertension; D015736:Felodipine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000959:Antihypertensive Agents; D004095:Dihydropyridines; C059427:aranidipine; D015736:Felodipine